Drug profile · INN
enalapril maleate
AQUMELDI
enalapril maleate (AQUMELDI) is a angiotensin-converting enzyme inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — enalapril maleate
- US status
- approved
- Class
- Cardiovascular system (C09)
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
enalapril maleate (AQUMELDI) is a angiotensin-converting enzyme inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Angiotensin-converting enzyme inhibitor
Primary target: Angiotensin-converting enzyme
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is enalapril maleate?
enalapril maleate (AQUMELDI) is a angiotensin-converting enzyme inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for enalapril maleate?
AQUMELDI is a marketed brand name for enalapril maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of enalapril maleate?
enalapril maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.